Sandoz (SIX:SDZ / OTCQX:SDZNY), the global leader in affordable medicines, will host its 2026 capital markets day for investors and analysts on Tuesday, 8 September, at the London Stock Exchange. The event, running from 13:30 to 17:00 UK time, will be available via live webcast, with in-person attendance by invitation only on a first-come, first-served basis. The formal part of the event will begin at 13:30, and details on accessing the live webcast are available here.
In addition, Sandoz plans to host an investor and analyst site visit in Slovenia from 9-10 November, offering deeper insight into the company's new biosimilars development and supply-chain hub. Attendance will also be by invitation only on a first-come, first-served basis, and the event will not be webcasted.
The capital markets day comes as Sandoz navigates what it calls its "Golden Decade for Biosimilars," a period of significant growth driven by patent expiries on major biologic drugs. The company's focus on affordable medicines, particularly biosimilars, positions it to capture market share and generate substantial healthcare savings. Sandoz's portfolio of approximately 1,300 medicines addresses diseases from the common cold to cancer, and in 2025, it recorded net sales of USD 11.1 billion.
Sandoz, headquartered in Basel, Switzerland, traces its heritage back to 1886. In 2026, the company celebrates 20 years of pioneering biosimilars, 80 years of antibiotics manufacturing, and 140 years of heritage. With more than 20,000 colleagues of 100 nationalities, Sandoz reaches over one billion patients worldwide, generating substantial global healthcare savings and an even larger social impact.
The capital markets day and site visit are expected to provide investors with a clear view of Sandoz's growth strategy, including its focus on biosimilars, which are lower-cost versions of biologic drugs. As biosimilars gain traction in markets like the US and Europe, Sandoz aims to maximize value for shareholders while expanding patient access to essential medicines.
Forward-looking statements in the announcement caution that actual outcomes may vary materially due to risks such as global economic conditions, exchange rates, legal provisions, market conditions, and competitor activities. Sandoz undertakes no obligation to publicly revise any forward-looking statements, except as required by law.
